Subjects
who received nalmefene had a statistically significant reduction in severity
of pathological gambling.clinicaltrials.

About Pathological Gambling
Impulse control disorders affect millions of Americans and have been
recognized by the Diagnostic and Statistical Manual of Mental Disorders as a
clinical diagnosis since 1980.

nutz schizophrenia

While the Food and Drug Administration has
approved this drug for the treatment of depression, it has not been
approved for treatment of dysthymia.
It is just an illness that starts early in life and persists.
(Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing
and development of product candidates for the treatment of psychiatric and
neurological disorders, today said that the February 2006 issue of the
American Journal of Psychiatry features an article which describes the conduct
and results of a four-month clinical trial investigating the efficacy and
safety of one of its product candidates, oral nalmefene hydrochloride , an
opioid antagonist, in reducing pathological gambling-related urges, thoughts
and behaviors .
According to Datamonitor, potentially 6.4 million persons in the United States
suffer from intermittent explosive disorder.

About Somaxon Pharmaceuticals
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. This caution is made
under the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995.C.

impulse neurodevelopmental

The American Journal of Psychiatry Publishes Data on Clinical Trial of Nalmefene in the Treatment of Pathological Gambling

Although estimates of the market
for compulsive buying vary widely, based on a report in the 2004 Annals of
Clinical Psychiatry; we believe the prevalence of this disorder ranges from
1.1% to 5. All forward-looking
statements are qualified in their entirety by this cautionary statement and
Somaxon undertakes no obligation to revise or update this news release to
reflect events or circumstances after the date hereof.
Many of these conditions are common and require life-long treatment.
- The American Diabetes Association, the American Psychiatric
Association, the American Association of Clinical Endocrinologists and
the North American Association for the Study of Obesity issued a joint
statement confirming the association between Zyprexa and diabetes in
February 2004 .

adhd personality

Participants are required to make 10 visits to the clinic over a
period of 13 weeks, and participants will be interviewed at those
times.
To be eligible for the study, subjects must be age 18 or older ,
and in relatively good health.
Somaxon is currently enrolling patients in an ongoing, multi -center Phase
II/III clinical trial investigating the use of oral nalmefene for this
indication .9% of American adults, or 2.
- At least 23 deaths have been associated with Zyprexa use to date .

bipolar narcissistic

"Since dysthymia usually starts before age 21, most people who
have it think it's just 'part of my personality -- I have always been
that way,'" said Lorrin Koran, MD, professor of psychiatry and
behavioral sciences. The impulse control disorder category includes pathological
gambling , kleptomania, pyromania, intermittent explosive disorder and
compulsive buying.
In particular , the pervasiveness of internet gambling is a potential
facilitating factor in youth gambling.4 to 13., Pharmaceutical giant Eli-Lilly +
Company has agreed to pay $700 million to members of a product liability group
settlement, ending a six-month negotiation between the company and attorneys
representing over 7,000 affected users of the anti-depressant drug Zyprexa
(Olanzapine).

anonymously borderline

The author of the article, Jon Grant, M.5980) or visit the company's website at
http://www. Lopez of
Lopez, Hodes, and Restaino; and Nancy Hersh of Hersh + Hersh. Pleasant, and Barnwell, S.

trichotillomania babble

Dysthymia is defined as chronic sad or depressed mood, accompanied
by additional symptoms such as sleep disturbances, low self-esteem,
difficulty concentrating or making decisions, low energy, feelings of
hopelessness and/or weight or appetite change.

babble healthyplace

Eli Lilly + Co, the maker of duloxetine,
is funding the study. "In fact, it is not part of personality at all."
Koran, lead investigator on the study , said he believes treatment
is important to relieve unnecessary suffering, to improve functioning
in work and family roles, to allow normal enjoyment of life's rewards
and to prevent the onset of major depression, with its great risk of
total disability and suicidal behaviors. The 25 mg nalmefene dose appeared to be efficacious
and was better tolerated than the 50 mg and 100 mg doses. The
Gambling Impact and Behavior Study of 1999 found that approximately 3.

healthyplace grohol

The drug acts to increase the
availability of two chemical messengers in the brain, serotonin and
norepinephrine, both of which are involved in the abnormal physiology
that gives rise to depression and dysthymia. is a
specialty pharmaceutical company focused on the in-licensing and development
of proprietary product candidates for the treatment of diseases and disorders
in the fields of psychiatry and neurology. (310. For
more information , visit http://www.

personality mental

Each visit should last about an hour, except for the initial
screening visit, which will last approximately three hours and will
include a physical examination and laboratory tests that involve
providing a blood sample. For more information, please
visit the Web site of the medical center's Office of Communication +
Public Affairs at http://mednews.somaxon. The
inclusion of forward-looking statements should not be regarded as a
representation by Somaxon that any of its plans will be achieved.L.

antisocial bitch

----Having trouble
making decisions? Struggling with feelings of hopelessness? Suffering
from low self-esteem?
Researchers at the Stanford University School of Medicine need
volunteers who are suffering from these and other symptoms to test the
safety and efficacy of a drug for the treatment of dysthymia, a
low-grade and long-lasting type of depression. It affects 3 to 6
percent of the adult population in the United States and differs from
"regular depression " -- what is commonly referred to as major
depression -- in having fewer symptoms present at one time (three to
five vs.edu

Actual
results may differ materially from those set forth in this release due to the
risks and uncertainties inherent in Somaxon's business, including, without
limitation: the progress and timing of clinical trials, including for
nalmefene and Somaxon's other product candidates; unexpected adverse side
effects or inadequate therapeutic efficacy of nalmefene or Somaxon's other
product candidates that could delay or prevent regulatory approval, product
development or commercialization, or that could result in product liability
claims; the scope and validity of patent protection for nalmefene and
Somaxon's other product candidates; the market potential for impulse control
disorders and Somaxon's other target markets, and Somaxon's ability to
compete; and other risks detailed in Somaxon's prior press releases as well as
in public periodic filings with the Securities and Exchange Commission. Since that time, Zyprexa has been approved
for treatment of acute bipolar mania and is regularly prescribed for mental
disorders ranging from schizophrenia , dementia, autism, aggressive behavior,
personality disorders, post-traumatic stress disorder to severe depression.com.

antisocial borderline

stanford.
BioTie Therapies Corp. of Finland sponsored the trial, which was completed
in April 2003. The trial compared three doses of
nalmefene (25 mg, 50 mg and 100 mg/day) to placebo.5 million pathological gamblers, 3 million problem gamblers
and an additional 15 million people who are at-risk for pathological gambling.279.

mental borderline

D. Other disorders such as intermittent
explosive disorder and compulsive buying are also significant problems.0 million American adults . Seeger of Seeger Weiss, L.C.

bpd impulse

In November 2004, Somaxon entered into an exclusive license
with BioTie to certain patents to develop, manufacture, and market nalmefene
in North America. at the University of
Minnesota, was a lead investigator in the trial.gov.

Contact:
Meg McGilley, Chief Financial Officer (858. The attorneys formed a Plaintiff's Negotiating
Committee to facilitate reaching a settlement with Eli Lilly.L.K.

bereavement frustrations

Business Editors/Health/Medical Writers

STANFORD , Calif.
This is an open-label study with no placebo, meaning that everyone
in the study will receive the drug. They cannot be pregnant or
breastfeeding, have problems with drugs or alcohol or have other major
psychiatric diagnoses such as bipolar disorder.; Christopher A.
Zyprexa, manufactured by Eli Lilly + Company, is an "atypical" anti-
psychotic medication that received FDA approval for the treatment of
schizophrenia in September 1996. The firm has
locations in Chicago and in Charleston , Mt.rpwb.

healthyplace overwhelmed

five to 12). Dysthymia sufferers are less likely to go to
college, complete college and get a job consistent with their
educational level, and the condition is associated with increased loss
of work time as well as decreased life satisfaction.5% of 16
to 17 year-olds could be considered at-risk, problem or pathological gamblers. Attorneys in
the committee included Blair Hahn of Richardson Patrick Westbrook + Brickman,
L.P.
- The FDA asked Eli Lilly to add a warning about the risk of diabetes and
other hypoglycemia-related diseases on labels for Zyprexa in September
2003.
- Zyprexa's label now lists diabetes as a potential "adverse event.

Specific details of the settlement were not available at the time of this
release.

anonymously bpd

You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof.
Last year, Zyprexa, the world's top selling schizophrenia drug, made up
almost 50 % of Eli Lilly's total pharmaceutical sales., and $4 billion annually
worldwide.L.

mental antisocial

To sign up or to obtain additional information, please contact the
research study line at (650) 725-5180.; Ramon R.

narcissistic bipolar

The primary endpoint
consisted of mean change from baseline on the Yale Brown Obsessive Compulsive
Scale modified for Pathological Gambling, a clinician-administered
questionnaire for assessing gambling thoughts/urges and behavior.3670), or Rob Whetsone,
PondelWilkinson, Inc.S.

geeks bereavement

Volunteers Needed for Stanford Study of Drug for Mild Depression

Information regarding nalmefene clinical trials sponsored by
Somaxon may be found on the website http://www.

Somaxon cautions you that statements included in this press release that
are not a description of historical facts are forward -looking statements.

Eli Lilly + Company to Pay $700 Million in Product Liability Group Settlement - First of Its Kind Against Zyprexa

dmda bpd

Stanford University Medical Center integrates research, medical
education and patient care at its three institutions -- Stanford
University School of Medicine , Stanford Hospital + Clinics and Lucile
Packard Children's Hospital at Stanford. SAN DIEGO, Somaxon Pharmaceuticals, Inc.com., is one of the leading
complex litigation firms in the country with extensive expertise in tobacco,
asbestos, securities fraud, and other complex mass torts.

Support groups for people with mental health conditions.

impulse pathological

Volunteers will be prescreened and, if eligible, will receive the
drug duloxetine for 12 weeks.

personality bereavement

The randomized,
placebo-controlled, double-blind, multi-center trial included 207 subjects
diagnosed as pathological gamblers.509. have required warnings concerning
Zyprexa and diabetes for many years.

nutz grohol

The Diagnostic and Statistical Manual of
Mental Disorders -- Fourth Edition, published by the American Psychiatric
Association, is the standard reference manual used to classify and diagnose
mental disorders. The University of Chicago 's 1999 Gambling Impact and
Behavior Study estimates that in the United States alone, there are
approximately 2.
There is also growing evidence of problematic adolescent gambling. Somaxon's lead product candidate ,
SILENOR(TM) (doxepin hydrochloride), is in Phase III clinical trials for the
treatment of insomnia . Estimates put Zyprexa's
sales between $2 billion annually in the U.

Some brief facts on Zyprexa:
- Zyprexa was associated with a 37% increase in the risk of development
of diabetes as compared to other atypical anti-psychotic medications."
Nations such as Japan and the U.

dmda pathological

, J.D. Nationwide Team of Attorneys Join Forces in Effort Against Manufacturer of
Anti-Depressant Drug Zyprexa

CHARLESTON, S.
A team of attorneys from across the country joined forces in the effort
against Eli Lilly + Company, the producer of Zyprexa -- an anti-depressant
drug that has been shown to greatly increase the risk of diabetes or
hypoglycemia-related diseases.C.

Richardson, Patrick, Westbrook + Brickman, L.